Citius Pharmaceuticals Inc
Company Profile
Business description
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Contact
11 Commerce Drive
First Floor
CranfordNJ07016
USAT: +1 908 967-6677
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
23
Stocks News & Analysis
stocks
Wide moat share remains cheap despite rising costs
stocks
Fair value upgrade for ASX listed fast food chain
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,374.90 | 50.40 | 0.54% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,511.10 | 6.23 | -0.02% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 65,856.43 | 328.34 | 0.50% |
| NZX 50 Index | 13,992.72 | 110.84 | 0.80% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,164.60 | 54.30 | 0.60% |
| SSE Composite Index | 3,889.44 | 7.44 | 0.19% |